St Andrews-based Eos Advisory has entered into a strategic partnership with Kineticos to co-invest in early-stage Scottish life sciences companies.

They aim to invest more than £10m over five years in “oncology-focused” firms.

For full article click here:

About Kineticos Disruptor Fund:

You have ideas, we have funding. Through Kineticos and our related Kineticos Disruptor Fund, we invest in select sponsors to advance clinical research. With multiple modes of engagement such as fee for service, hybrid fee for service/success based and equity arrangements, we have viable options for companies at any stage of development.

About Eos Advisory:

Eos Advisory is focused on providing seed funding to ventures based upon strong and innovative science, technology and engineering. We commit to supporting them through their early development and on to their next stage of growth funding, at which point we will work with strategic investors to maximize the growth as well as the exit potential.